Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Boris Kin Lin"'
Autor:
Talia Golan, Ravit Geva, Donald Richards, Srinivasan Madhusudan, Boris Kin Lin, Haofei Tiffany Wang, Richard A. Walgren, Salomon M. Stemmer
Publikováno v:
Journal of Cachexia, Sarcopenia and Muscle, Vol 9, Iss 5, Pp 871-879 (2018)
Abstract Background Cachexia is a formidable clinical challenge in pancreatic cancer. We assessed LY2495655 (antimyostatin antibody) plus standard‐of‐care chemotherapy in pancreatic cancer using cachexia status as a stratifier. Methods In this ra
Externí odkaz:
https://doaj.org/article/08dd0a4842b84ca2856eae3aecb137c3
Autor:
Johanna C. Bendell, Boris Kin Lin, Sophie Callies, Anna M. Szpurka, Gregory P. Donoho, Volker Wacheck, Wei Zhang, Susan C. Guba, Paul R. Sieber, Neal D. Shore, Costantine Albany, Ian D. Schnadig, David S. Morris, Oscar B. Goodman, Bryan A. Mehlhaff, Jennifer L. Cultrera, Sunil Babu, Ivor J. Percent, Christopher J. Sweeney
Supplementary Figure from Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::224daf568721c80e465b0dae93e74292
https://doi.org/10.1158/1078-0432.22482390.v1
https://doi.org/10.1158/1078-0432.22482390.v1
Autor:
Johanna C. Bendell, Boris Kin Lin, Sophie Callies, Anna M. Szpurka, Gregory P. Donoho, Volker Wacheck, Wei Zhang, Susan C. Guba, Paul R. Sieber, Neal D. Shore, Costantine Albany, Ian D. Schnadig, David S. Morris, Oscar B. Goodman, Bryan A. Mehlhaff, Jennifer L. Cultrera, Sunil Babu, Ivor J. Percent, Christopher J. Sweeney
Purpose:To report efficacy and safety of samotolisib (LY3023414; PI3K/mTOR dual kinase and DNA-dependent protein kinase inhibitor) plus enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) following cancer progression
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a955fdf62bcabf4dd78a334c5904c2c
https://doi.org/10.1158/1078-0432.c.6530910
https://doi.org/10.1158/1078-0432.c.6530910
Autor:
Christopher J. Sweeney, Ivor J. Percent, Sunil Babu, Jennifer L. Cultrera, Bryan A. Mehlhaff, Oscar B. Goodman, David S. Morris, Ian D. Schnadig, Costantine Albany, Neal D. Shore, Paul R. Sieber, Susan C. Guba, Wei Zhang, Volker Wacheck, Gregory P. Donoho, Anna M. Szpurka, Sophie Callies, Boris Kin Lin, Johanna C. Bendell
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 28(11)
Purpose: To report efficacy and safety of samotolisib (LY3023414; PI3K/mTOR dual kinase and DNA-dependent protein kinase inhibitor) plus enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) following cancer progressio